Search

Your search keyword '"Greninger, Patricia"' showing total 371 results
Start Over Author "Greninger, Patricia"
371 results on '"Greninger, Patricia"'

1. IFITM proteins assist cellular uptake of diverse linked chemotypes

Author

Lou, Kevin, Wassarman, Douglas R, Yang, Tangpo, Paung, YiTing, Zhang, Ziyang, O'Loughlin, Thomas A, Moore, Megan K, Egan, Regina K, Greninger, Patricia, Benes, Cyril H, Seeliger, Markus A, Taunton, Jack, Gilbert, Luke A, and Shokat, Kevan M

Subjects
Biochemistry and Cell Biology, Medicinal and Biomolecular Chemistry, Chemical Sciences, Biological Sciences, Orphan Drug, Rare Diseases, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, General Science & Technology
Abstract

The search for cell-permeable drugs has conventionally focused on low-molecular weight (MW), nonpolar, rigid chemical structures. However, emerging therapeutic strategies break traditional drug design rules by employing flexibly linked chemical entities composed of more than one ligand. Using complementary genome-scale chemical-genetic approaches we identified an endogenous chemical uptake pathway involving interferon-induced transmembrane proteins (IFITMs) that modulates the cell permeability of a prototypical biopic inhibitor of MTOR (RapaLink-1, MW: 1784 g/mol). We devised additional linked inhibitors targeting BCR-ABL1 (DasatiLink-1, MW: 1518 g/mol) and EIF4A1 (BisRoc-1, MW: 1466 g/mol), uptake of which was facilitated by IFITMs. We also found that IFITMs moderately assisted some proteolysis-targeting chimeras and examined the physicochemical requirements for involvement of this uptake pathway.

Published
2022

2. A landscape of response to drug combinations in non-small cell lung cancer

Author

Nair, Nishanth Ulhas, Greninger, Patricia, Zhang, Xiaohu, Friedman, Adam A., Amzallag, Arnaud, Cortez, Eliane, Sahu, Avinash Das, Lee, Joo Sang, Dastur, Anahita, Egan, Regina K., Murchie, Ellen, Ceribelli, Michele, Crowther, Giovanna S., Beck, Erin, McClanaghan, Joseph, Klump-Thomas, Carleen, Boisvert, Jessica L., Damon, Leah J., Wilson, Kelli M., Ho, Jeffrey, Tam, Angela, McKnight, Crystal, Michael, Sam, Itkin, Zina, Garnett, Mathew J., Engelman, Jeffrey A., Haber, Daniel A., Thomas, Craig J., Ruppin, Eytan, and Benes, Cyril H.

Published
2023
Full Text
View/download PDF

3. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Wu, Qibiao, Zhen, Yuanli, Shi, Lei, Vu, Phuong, Greninger, Patricia, Adil, Ramzi, Merritt, Joshua, Egan, Regina, Wu, Meng-Ju, Yin, Xunqin, Ferrone, Cristina R, Deshpande, Vikram, Baiev, Islam, Pinto, Christopher J, McLoughlin, Daniel E, Walmsley, Charlotte S, Stone, James R, Gordan, John D, Zhu, Andrew X, Juric, Dejan, Goyal, Lipika, Benes, Cyril H, and Bardeesy, Nabeel

Subjects
Digestive Diseases - (Gallbladder), Digestive Diseases, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Cholangiocarcinoma, ErbB Receptors, Humans, Protein Kinase Inhibitors, Pyrimidines, Receptor, Fibroblast Growth Factor, Type 2, Oncology and Carcinogenesis
Abstract

FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined mechanisms. Here, we conducted high-throughput combination drug screens, biochemical analysis, and therapeutic studies using patient-derived models of FGFR2 fusion-positive cholangiocarcinoma to gain insight into these clinical profiles and uncover improved treatment strategies. We found that feedback activation of EGFR signaling limits FGFR inhibitor efficacy, restricting cell death induction in sensitive models and causing resistance in insensitive models lacking secondary FGFR2 mutations. Inhibition of wild-type EGFR potentiated responses to FGFR inhibitors in both contexts, durably suppressing MEK/ERK and mTOR signaling, increasing apoptosis, and causing marked tumor regressions in vivo. Our findings reveal EGFR-dependent adaptive signaling as an important mechanism limiting FGFR inhibitor efficacy and driving resistance and support clinical testing of FGFR/EGFR inhibitor therapy for FGFR2 fusion-positive cholangiocarcinoma.SignificanceWe demonstrate that feedback activation of EGFR signaling limits the effectiveness of FGFR inhibitor therapy and drives adaptive resistance in patient-derived models of FGFR2 fusion-positive cholangiocarcinoma. These studies support the potential of combination treatment with FGFR and EGFR inhibitors as an improved treatment for patients with FGFR2-driven cholangiocarcinoma. This article is highlighted in the In This Issue feature, p. 1171.

Published
2022

4. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers

Author

Shi, Lei, Shen, William, Davis, Mindy I., Kong, Ke, Vu, Phuong, Saha, Supriya K., Adil, Ramzi, Kreuzer, Johannes, Egan, Regina, Lee, Tobie D., Greninger, Patricia, Shrimp, Jonathan H., Zhao, Wei, Wei, Ting-Yu, Zhou, Mi, Eccleston, Jason, Sussman, Jonathan, Manocha, Ujjawal, Weerasekara, Vajira, Kondo, Hiroshi, Vijay, Vindhya, Wu, Meng-Ju, Kearney, Sara E., Ho, Jeffrey, McClanaghan, Joseph, Murchie, Ellen, Crowther, Giovanna S., Patnaik, Samarjit, Boxer, Matthew B., Shen, Min, Ting, David T., Kim, William Y., Stanger, Ben Z., Deshpande, Vikram, Ferrone, Cristina R., Benes, Cyril H., Haas, Wilhelm, Hall, Matthew D., and Bardeesy, Nabeel

Published
2023
Full Text
View/download PDF

5. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.

Author

Sahu, Avinash, S Lee, Joo, Wang, Zhiyong, Zhang, Gao, Iglesias-Bartolome, Ramiro, Tian, Tian, Wei, Zhi, Miao, Benchun, Nair, Nishanth, Ponomarova, Olga, Friedman, Adam, Amzallag, Arnaud, Moll, Tabea, Kasumova, Gyulnara, Greninger, Patricia, Egan, Regina, Damon, Leah, Frederick, Dennie, Jerby-Arnon, Livnat, Wagner, Allon, Cheng, Kuoyuan, Park, Seung, Robinson, Welles, Gardner, Kevin, Boland, Genevieve, Hannenhalli, Sridhar, Herlyn, Meenhard, Benes, Cyril, Flaherty, Keith, Luo, Ji, Gutkind, J, and Ruppin, Eytan

Subjects
drug combination, drug resistance, immunotherapy, synergy, Computational Biology, Drug Resistance, Neoplasm, Drug Synergism, Female, Gene Expression Profiling, Humans, Immunotherapy, Male, Melanoma, Molecular Targeted Therapy, Synthetic Lethal Mutations
Abstract

Most patients with advanced cancer eventually acquire resistance to targeted therapies, spurring extensive efforts to identify molecular events mediating therapy resistance. Many of these events involve synthetic rescue (SR) interactions, where the reduction in cancer cell viability caused by targeted gene inactivation is rescued by an adaptive alteration of another gene (the rescuer). Here, we perform a genome-wide in silico prediction of SR rescuer genes by analyzing tumor transcriptomics and survival data of 10,000 TCGA cancer patients. Predicted SR interactions are validated in new experimental screens. We show that SR interactions can successfully predict cancer patients response and emerging resistance. Inhibiting predicted rescuer genes sensitizes resistant cancer cells to therapies synergistically, providing initial leads for developing combinatorial approaches to overcome resistance proactively. Finally, we show that the SR analysis of melanoma patients successfully identifies known mediators of resistance to immunotherapy and predicts novel rescuers.

Published
2019

7. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma

Author

Dalton, Krista M., Lochmann, Timothy L., Floros, Konstantinos V., Calbert, Marissa L., Kurupi, Richard, Stein, Giovanna T., McClanaghan, Joseph, Murchie, Ellen, Egan, Regina K., Greninger, Patricia, Dozmorov, Mikhail, Ramamoorthy, Sivapriya, Puchalapalli, Madhavi, Hu, Bin, Shock, Lisa, Koblinski, Jennifer, Glod, John, Boikos, Sosipatros A., Benes, Cyril H., and Faber, Anthony C.

Published
2021

8. Differential Effector Engagement by Oncogenic KRAS

Author

Yuan, Tina L, Amzallag, Arnaud, Bagni, Rachel, Yi, Ming, Afghani, Shervin, Burgan, William, Fer, Nicole, Strathern, Leslie A, Powell, Katie, Smith, Brian, Waters, Andrew M, Drubin, David, Thomson, Ty, Liao, Rosy, Greninger, Patricia, Stein, Giovanna T, Murchie, Ellen, Cortez, Eliane, Egan, Regina K, Procter, Lauren, Bess, Matthew, Cheng, Kwong Tai, Lee, Chih-Shia, Lee, Liam Changwoo, Fellmann, Christof, Stephens, Robert, Luo, Ji, Lowe, Scott W, Benes, Cyril H, and McCormick, Frank

Subjects
Biochemistry and Cell Biology, Biological Sciences, Lung, Cancer, AMP-Activated Protein Kinase Kinases, Adenylate Kinase, Cell Line, Tumor, Drug Evaluation, Preclinical, Gene Expression Regulation, Neoplastic, Humans, Metabolic Networks and Pathways, Models, Biological, Mutation, Oncogenes, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins p21(ras), RNA Interference, RNA, Small Interfering, Small Molecule Libraries, KRAS, RNAi screen, RSK, paralogs, redundancy, Medical Physiology, Biological sciences
Abstract

KRAS can bind numerous effector proteins, which activate different downstream signaling events. The best known are RAF, phosphatidylinositide (PI)-3' kinase, and RalGDS families, but many additional direct and indirect effectors have been reported. We have assessed how these effectors contribute to several major phenotypes in a quantitative way, using an arrayed combinatorial siRNA screen in which we knocked down 41 KRAS effectors nodes in 92 cell lines. We show that every cell line has a unique combination of effector dependencies, but in spite of this heterogeneity, we were able to identify two major subtypes of KRAS mutant cancers of the lung, pancreas, and large intestine, which reflect different KRAS effector engagement and opportunities for therapeutic intervention.

Published
2018

9. Screening and Validation of Molecular Targeted Radiosensitizers

Author

Willers, Henning, Pan, Xiao, Borgeaud, Nathalie, Korovina, Irina, Koi, Lydia, Egan, Regina, Greninger, Patricia, Rosenkranz, Aliza, Kung, Jong, Liss, Andrew S., Parsels, Leslie A., Morgan, Meredith A., Lawrence, Theodore S., Lin, Steven H., Hong, Theodore S., Yeap, Beow Y., Wirth, Lori J., Hata, Aaron N., Ott, Christopher J., Benes, Cyril H., Baumann, Michael, and Krause, Mechthild

Published
2021
Full Text
View/download PDF

10. Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer

Author

Wang, Yuezhou, Zhang, Lei, Wei, Yanling, Huang, Wei, Li, Li, Wu, An-an, Dastur, Anahita, Greninger, Patricia, Bray, Walter M., Zhang, Chen-Song, Li, Mengqi, Lian, Wenhua, Hu, Zhiyu, Wang, Xiaoyong, Liu, Gang, Yao, Luming, Guh, Jih-Hwa, Chen, Lanfen, Wang, Hong-Rui, Zhou, Dawang, Lin, Sheng-Cai, Xu, Qingyan, Shen, Yuemao, Zhang, Jianming, Jurica, Melissa S., Benes, Cyril H., and Deng, Xianming

Published
2020
Full Text
View/download PDF

11. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Author

Saha, Supriya K, Gordan, John D, Kleinstiver, Benjamin P, Vu, Phuong, Najem, Mortada S, Yeo, Jia-Chi, Shi, Lei, Kato, Yasutaka, Levin, Rebecca S, Webber, James T, Damon, Leah J, Egan, Regina K, Greninger, Patricia, McDermott, Ultan, Garnett, Mathew J, Jenkins, Roger L, Rieger-Christ, Kimberly M, Sullivan, Travis B, Hezel, Aram F, Liss, Andrew S, Mizukami, Yusuke, Goyal, Lipika, Ferrone, Cristina R, Zhu, Andrew X, Joung, J Keith, Shokat, Kevan M, Benes, Cyril H, and Bardeesy, Nabeel

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Digestive Diseases - (Gallbladder), Cancer, Liver Disease, Orphan Drug, Liver Cancer, Digestive Diseases, Rare Diseases, Biotechnology, Aetiology, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Bile Duct Neoplasms, Cell Line, Tumor, Cell Proliferation, Cholangiocarcinoma, Cluster Analysis, Dasatinib, Disease Models, Animal, Drug Resistance, Neoplasm, Gene Expression Profiling, Humans, Isocitrate Dehydrogenase, Mice, Mutation, Xenograft Model Antitumor Assays, src-Family Kinases, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

UnlabelledIntrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, we found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib, with the highest sensitivity among 682 solid tumor cell lines. Using unbiased proteomics to capture the activated kinome and CRISPR/Cas9-based genome editing to introduce dasatinib-resistant "gatekeeper" mutant kinases, we identified SRC as a critical dasatinib target in IDHm ICC. Importantly, dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression. Our results show that IDHm ICC cells have a unique dependency on SRC and suggest that dasatinib may have therapeutic benefit against IDHm ICC. Moreover, these proteomic and genome-editing strategies provide a systematic and broadly applicable approach to define targets of kinase inhibitors underlying drug responsiveness.SignificanceIDH mutations define a distinct subtype of ICC, a malignancy that is largely refractory to current therapies. Our work demonstrates that IDHm ICC cells are hypersensitive to dasatinib and critically dependent on SRC activity for survival and proliferation, pointing to new therapeutic strategies against these cancers. Cancer Discov; 6(7); 727-39. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 681.

Published
2016

12. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, Frumm, Stacey M, Alexe, Gabriela, Bassil, Christopher F, Qi, Jun, Chanthery, Yvan H, Nekritz, Erin A, Zeid, Rhamy, Gustafson, William Clay, Greninger, Patricia, Garnett, Matthew J, McDermott, Ultan, Benes, Cyril H, Kung, Andrew L, Weiss, William A, Bradner, James E, and Stegmaier, Kimberly

Subjects
Human Genome, Pediatric Research Initiative, Genetics, Pediatric Cancer, Clinical Research, Pediatric, Neuroblastoma, Neurosciences, Rare Diseases, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Apoptosis, Azepines, Cell Cycle Checkpoints, Cell Cycle Proteins, Cell Growth Processes, Cell Line, Tumor, Child, Down-Regulation, Female, Gene Amplification, Humans, Mice, Molecular Targeted Therapy, N-Myc Proto-Oncogene Protein, Nuclear Proteins, Oncogene Proteins, Promoter Regions, Genetic, Protein Structure, Tertiary, Proto-Oncogene Proteins c-myc, RNA, Small Interfering, Transcription Factors, Transfection, Triazoles, Xenograft Model Antitumor Assays, Oncology and Carcinogenesis
Abstract

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a robust correlation between MYCN amplification and sensitivity to bromodomain inhibition. We characterized the mechanistic and translational significance of this finding in neuroblastoma, a childhood cancer with frequent amplification of MYCN. Genome-wide expression analysis showed downregulation of the MYCN transcriptional program accompanied by suppression of MYCN transcription. Functionally, bromodomain-mediated inhibition of MYCN impaired growth and induced apoptosis in neuroblastoma. BRD4 knockdown phenocopied these effects, establishing BET bromodomains as transcriptional regulators of MYCN. BET inhibition conferred a significant survival advantage in 3 in vivo neuroblastoma models, providing a compelling rationale for developing BET bromodomain inhibitors in patients with neuroblastoma.

Published
2013

13. Figure S5 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

Author

Kurupi, Richard, primary, Floros, Konstantinos V., primary, Jacob, Sheeba, primary, Chawla, Ayesha T., primary, Cai, Jinyang, primary, Hu, Bin, primary, Puchalapalli, Madhavi, primary, Coon, Colin M., primary, Khatri, Rishabh, primary, Crowther, Giovanna Stein, primary, Egan, Regina K., primary, Murchie, Ellen, primary, Greninger, Patricia, primary, Dalton, Krista M., primary, Ghotra, Maninderjit S., primary, Boikos, Sosipatros A., primary, Koblinski, Jennifer E., primary, Harada, Hisashi, primary, Sun, Yue, primary, Morgan, Iain M., primary, Basu, Devraj, primary, Dozmorov, Mikhail G., primary, Benes, Cyril H., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

14. Table S1 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

Author

Kurupi, Richard, primary, Floros, Konstantinos V., primary, Jacob, Sheeba, primary, Chawla, Ayesha T., primary, Cai, Jinyang, primary, Hu, Bin, primary, Puchalapalli, Madhavi, primary, Coon, Colin M., primary, Khatri, Rishabh, primary, Crowther, Giovanna Stein, primary, Egan, Regina K., primary, Murchie, Ellen, primary, Greninger, Patricia, primary, Dalton, Krista M., primary, Ghotra, Maninderjit S., primary, Boikos, Sosipatros A., primary, Koblinski, Jennifer E., primary, Harada, Hisashi, primary, Sun, Yue, primary, Morgan, Iain M., primary, Basu, Devraj, primary, Dozmorov, Mikhail G., primary, Benes, Cyril H., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

15. Data from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Wu, Qibiao, primary, Zhen, Yuanli, primary, Shi, Lei, primary, Vu, Phuong, primary, Greninger, Patricia, primary, Adil, Ramzi, primary, Merritt, Joshua, primary, Egan, Regina, primary, Wu, Meng-Ju, primary, Yin, Xunqin, primary, Ferrone, Cristina R., primary, Deshpande, Vikram, primary, Baiev, Islam, primary, Pinto, Christopher J., primary, McLoughlin, Daniel E., primary, Walmsley, Charlotte S., primary, Stone, James R., primary, Gordan, John D., primary, Zhu, Andrew X., primary, Juric, Dejan, primary, Goyal, Lipika, primary, Benes, Cyril H., primary, and Bardeesy, Nabeel, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Wu, Qibiao, primary, Zhen, Yuanli, primary, Shi, Lei, primary, Vu, Phuong, primary, Greninger, Patricia, primary, Adil, Ramzi, primary, Merritt, Joshua, primary, Egan, Regina, primary, Wu, Meng-Ju, primary, Yin, Xunqin, primary, Ferrone, Cristina R., primary, Deshpande, Vikram, primary, Baiev, Islam, primary, Pinto, Christopher J., primary, McLoughlin, Daniel E., primary, Walmsley, Charlotte S., primary, Stone, James R., primary, Gordan, John D., primary, Zhu, Andrew X., primary, Juric, Dejan, primary, Goyal, Lipika, primary, Benes, Cyril H., primary, and Bardeesy, Nabeel, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Wu, Qibiao, primary, Zhen, Yuanli, primary, Shi, Lei, primary, Vu, Phuong, primary, Greninger, Patricia, primary, Adil, Ramzi, primary, Merritt, Joshua, primary, Egan, Regina, primary, Wu, Meng-Ju, primary, Yin, Xunqin, primary, Ferrone, Cristina R., primary, Deshpande, Vikram, primary, Baiev, Islam, primary, Pinto, Christopher J., primary, McLoughlin, Daniel E., primary, Walmsley, Charlotte S., primary, Stone, James R., primary, Gordan, John D., primary, Zhu, Andrew X., primary, Juric, Dejan, primary, Goyal, Lipika, primary, Benes, Cyril H., primary, and Bardeesy, Nabeel, primary

Published
2023
Full Text
View/download PDF

18. Data from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

Author

Kurupi, Richard, primary, Floros, Konstantinos V., primary, Jacob, Sheeba, primary, Chawla, Ayesha T., primary, Cai, Jinyang, primary, Hu, Bin, primary, Puchalapalli, Madhavi, primary, Coon, Colin M., primary, Khatri, Rishabh, primary, Crowther, Giovanna Stein, primary, Egan, Regina K., primary, Murchie, Ellen, primary, Greninger, Patricia, primary, Dalton, Krista M., primary, Ghotra, Maninderjit S., primary, Boikos, Sosipatros A., primary, Koblinski, Jennifer E., primary, Harada, Hisashi, primary, Sun, Yue, primary, Morgan, Iain M., primary, Basu, Devraj, primary, Dozmorov, Mikhail G., primary, Benes, Cyril H., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

21. Data from Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Author

Ember, Stuart W., primary, Lambert, Que T., primary, Berndt, Norbert, primary, Gunawan, Steven, primary, Ayaz, Muhammad, primary, Tauro, Marilena, primary, Zhu, Jin-Yi, primary, Cranfill, Paula J., primary, Greninger, Patricia, primary, Lynch, Conor C., primary, Benes, Cyril H., primary, Lawrence, Harshani R., primary, Reuther, Gary W., primary, Lawrence, Nicholas J., primary, and Schönbrunn, Ernst, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table S1 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Author

Saha, Supriya K., primary, Gordan, John D., primary, Kleinstiver, Benjamin P., primary, Vu, Phuong, primary, Najem, Mortada S., primary, Yeo, Jia-Chi, primary, Shi, Lei, primary, Kato, Yasutaka, primary, Levin, Rebecca S., primary, Webber, James T., primary, Damon, Leah J., primary, Egan, Regina K., primary, Greninger, Patricia, primary, McDermott, Ultan, primary, Garnett, Mathew J., primary, Jenkins, Roger L., primary, Rieger-Christ, Kimberly M., primary, Sullivan, Travis B., primary, Hezel, Aram F., primary, Liss, Andrew S., primary, Mizukami, Yusuke, primary, Goyal, Lipika, primary, Ferrone, Cristina R., primary, Zhu, Andrew X., primary, Joung, J. Keith, primary, Shokat, Kevan M., primary, Benes, Cyril H., primary, and Bardeesy, Nabeel, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Author

Dalton, Krista M., primary, Krytska, Kateryna, primary, Lochmann, Timothy L., primary, Sano, Renata, primary, Casey, Colleen, primary, D'Aulerio, Alessia, primary, Khan, Qasim A., primary, Crowther, Giovanna Stein, primary, Coon, Colin, primary, Cai, Jinyang, primary, Jacob, Sheeba, primary, Kurupi, Richard, primary, Hu, Bin, primary, Dozmorov, Mikhail, primary, Greninger, Patricia, primary, Souers, Andrew J., primary, Benes, Cyril H., primary, Mossé, Yael P., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

26. Data from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Author

Saha, Supriya K., primary, Gordan, John D., primary, Kleinstiver, Benjamin P., primary, Vu, Phuong, primary, Najem, Mortada S., primary, Yeo, Jia-Chi, primary, Shi, Lei, primary, Kato, Yasutaka, primary, Levin, Rebecca S., primary, Webber, James T., primary, Damon, Leah J., primary, Egan, Regina K., primary, Greninger, Patricia, primary, McDermott, Ultan, primary, Garnett, Mathew J., primary, Jenkins, Roger L., primary, Rieger-Christ, Kimberly M., primary, Sullivan, Travis B., primary, Hezel, Aram F., primary, Liss, Andrew S., primary, Mizukami, Yusuke, primary, Goyal, Lipika, primary, Ferrone, Cristina R., primary, Zhu, Andrew X., primary, Joung, J. Keith, primary, Shokat, Kevan M., primary, Benes, Cyril H., primary, and Bardeesy, Nabeel, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Tables S4, S5 from Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Author

Ember, Stuart W., primary, Lambert, Que T., primary, Berndt, Norbert, primary, Gunawan, Steven, primary, Ayaz, Muhammad, primary, Tauro, Marilena, primary, Zhu, Jin-Yi, primary, Cranfill, Paula J., primary, Greninger, Patricia, primary, Lynch, Conor C., primary, Benes, Cyril H., primary, Lawrence, Harshani R., primary, Reuther, Gary W., primary, Lawrence, Nicholas J., primary, and Schönbrunn, Ernst, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Tables S1-S3 and Figures S1-S11 from Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Author

Ember, Stuart W., primary, Lambert, Que T., primary, Berndt, Norbert, primary, Gunawan, Steven, primary, Ayaz, Muhammad, primary, Tauro, Marilena, primary, Zhu, Jin-Yi, primary, Cranfill, Paula J., primary, Greninger, Patricia, primary, Lynch, Conor C., primary, Benes, Cyril H., primary, Lawrence, Harshani R., primary, Reuther, Gary W., primary, Lawrence, Nicholas J., primary, and Schönbrunn, Ernst, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 4 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Author

Dalton, Krista M., primary, Krytska, Kateryna, primary, Lochmann, Timothy L., primary, Sano, Renata, primary, Casey, Colleen, primary, D'Aulerio, Alessia, primary, Khan, Qasim A., primary, Crowther, Giovanna Stein, primary, Coon, Colin, primary, Cai, Jinyang, primary, Jacob, Sheeba, primary, Kurupi, Richard, primary, Hu, Bin, primary, Dozmorov, Mikhail, primary, Greninger, Patricia, primary, Souers, Andrew J., primary, Benes, Cyril H., primary, Mossé, Yael P., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Tables 1 - 9 from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legends, Figures S1 - S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Author

Saha, Supriya K., primary, Gordan, John D., primary, Kleinstiver, Benjamin P., primary, Vu, Phuong, primary, Najem, Mortada S., primary, Yeo, Jia-Chi, primary, Shi, Lei, primary, Kato, Yasutaka, primary, Levin, Rebecca S., primary, Webber, James T., primary, Damon, Leah J., primary, Egan, Regina K., primary, Greninger, Patricia, primary, McDermott, Ultan, primary, Garnett, Mathew J., primary, Jenkins, Roger L., primary, Rieger-Christ, Kimberly M., primary, Sullivan, Travis B., primary, Hezel, Aram F., primary, Liss, Andrew S., primary, Mizukami, Yusuke, primary, Goyal, Lipika, primary, Ferrone, Cristina R., primary, Zhu, Andrew X., primary, Joung, J. Keith, primary, Shokat, Kevan M., primary, Benes, Cyril H., primary, and Bardeesy, Nabeel, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Author

Dalton, Krista M., primary, Krytska, Kateryna, primary, Lochmann, Timothy L., primary, Sano, Renata, primary, Casey, Colleen, primary, D'Aulerio, Alessia, primary, Khan, Qasim A., primary, Crowther, Giovanna Stein, primary, Coon, Colin, primary, Cai, Jinyang, primary, Jacob, Sheeba, primary, Kurupi, Richard, primary, Hu, Bin, primary, Dozmorov, Mikhail, primary, Greninger, Patricia, primary, Souers, Andrew J., primary, Benes, Cyril H., primary, Mossé, Yael P., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures 1 -11 from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

45. Data from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legend from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Author

Dalton, Krista M., primary, Krytska, Kateryna, primary, Lochmann, Timothy L., primary, Sano, Renata, primary, Casey, Colleen, primary, D'Aulerio, Alessia, primary, Khan, Qasim A., primary, Crowther, Giovanna Stein, primary, Coon, Colin, primary, Cai, Jinyang, primary, Jacob, Sheeba, primary, Kurupi, Richard, primary, Hu, Bin, primary, Dozmorov, Mikhail, primary, Greninger, Patricia, primary, Souers, Andrew J., primary, Benes, Cyril H., primary, Mossé, Yael P., primary, and Faber, Anthony C., primary

Published
2023
Full Text
View/download PDF

50. Figure S2 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Author

Misale, Sandra, primary, Fatherree, Jackson P., primary, Cortez, Eliane, primary, Li, Chendi, primary, Bilton, Samantha, primary, Timonina, Daria, primary, Myers, David T., primary, Lee, Dana, primary, Gomez-Caraballo, Maria, primary, Greenberg, Max, primary, Nangia, Varuna, primary, Greninger, Patricia, primary, Egan, Regina K., primary, McClanaghan, Joseph, primary, Stein, Giovanna T., primary, Murchie, Ellen, primary, Zarrinkar, Patrick P., primary, Janes, Matthew R., primary, Li, Lian-Sheng, primary, Liu, Yi, primary, Hata, Aaron N., primary, and Benes, Cyril H., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results